Day One Biopharmaceuticals Reports Strong Revenue Growth and Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 30 2024
0mins
Should l Buy DAWN?
Source: Business Insider
Day One Biopharmaceuticals Inc shares surged by 25.62% as the stock crossed above its 5-day SMA, reflecting positive investor sentiment.
The company reported a preliminary net product revenue of $155.4 million for 2025, marking a 172% year-over-year increase, driven by strong demand for its treatment OJEMDA™ for pediatric low-grade glioma. Additionally, the acquisition of Mersana for $25 per share is expected to enhance Day One's oncology pipeline, particularly with the innovative Emi-Le program targeting rare cancers, further solidifying its market position.
This impressive revenue growth and strategic acquisition position Day One favorably for future expansion, with projected revenues for 2026 expected to reach between $225 million and $250 million, indicating a strong commitment to developing new therapies and addressing unmet medical needs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DAWN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DAWN
Wall Street analysts forecast DAWN stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.250
Low
16.00
Averages
22.29
High
29.00
Current: 21.250
Low
16.00
Averages
22.29
High
29.00
About DAWN
Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. It partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. OJEMDA is used for the treatment of patients over six months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Its pipeline product candidates include DAY301 and Emi-Le (emiltatug ledadotin). DAY301 is a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7. Emi-Le (emiltatug ledadotin) is a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Initiated: Halper Sadeh LLC is investigating Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) regarding its sale to Servier for $21.50 per share in cash, potentially infringing on shareholder rights, aiming to ensure fair treatment for investors.
- Shareholder Rights Protection: The firm is also scrutinizing Talkspace, Inc. (NASDAQ:TALK) in its sale to Universal Health Services, Inc. for $5.25 per share, urging shareholders to understand their rights and options to safeguard their interests.
- UniFirst Transaction Review: The sale of UniFirst Corporation (NYSE:UNF) to Cintas Corporation, offering $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, may prompt Halper Sadeh LLC to seek increased compensation and disclosures for shareholders to ensure transaction transparency.
- Global Investor Support: Halper Sadeh LLC represents investors worldwide, committed to combating securities fraud and corporate misconduct, having successfully recovered millions for victims in the past, highlighting its crucial role in protecting investor rights.
See More
Monteverde Law Firm Investigates Multiple Biopharma Companies
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the sale of Day One Biopharmaceuticals, with shareholders expected to receive $21.50 per share in cash, potentially providing significant financial returns and reflecting the company's market value in the biopharma sector.
- Medical Company Transaction: Shareholders of Select Medical Holdings are expected to receive $16.50 per share in cash, with the transaction led by Select Medical executives and directors, which may enhance the company's market position and boost shareholder confidence.
- FONAR Shareholder Returns: FONAR Corporation's Class B common stockholders will receive $19.00 per share, while Class C common stockholders will receive $6.34 per share, indicating a differentiated shareholder return strategy that could influence investor perceptions of the company's future.
- European Wax Center Acquisition: Shareholders of European Wax Center are expected to receive $5.80 per share in cash, with the transaction led by General Atlantic, which may provide new growth opportunities for the company while enhancing its competitiveness in the beauty industry.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Updates: The rating changes include upgrades, downgrades, and initiations, showcasing analysts' responsiveness to market dynamics, which may lead to short-term volatility in the affected stocks.
- Investor Focus: Investors considering buying VICI stock should pay attention to the latest analyst opinions, as these insights could provide crucial guidance for their investment decisions, particularly in the current market environment.
- Market Impact Analysis: Analyst rating changes typically have a direct impact on stock prices, prompting investors to closely monitor these shifts to adjust their investment strategies accordingly.
See More
Monteverde Law Firm Investigates Multiple Biopharmaceutical Companies
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the sale of Day One Biopharmaceuticals, Inc., where shareholders are expected to receive $21.50 per share in cash, providing substantial returns and enhancing market confidence in the biopharmaceutical sector.
- Merger Transaction Analysis: The merger between CECO Environmental Corp. and Thermon Group Holdings, Inc. is expected to grant CECO shareholders approximately 62.5% ownership in the combined company, significantly boosting CECO's market position in the environmental sector.
- Cash Acquisition Opportunity: Enhabit Inc.'s sale to Kinderhook Industries, LLC is projected to yield $13.80 per share for shareholders, reflecting a direct cash return that indicates market confidence in Enhabit's future growth prospects.
- Capital Investment Outlook: The transaction involving KORE Group Holdings, Inc. with Searchlight Capital Partners, L.P. and Abry Partners is expected to provide shareholders with $9.25 per share, offering stable cash flow and enhancing KORE's attractiveness in the capital markets.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these stocks.
- Market Dynamics Overview: While specific stock names are not mentioned, changes in analyst ratings typically influence investor decisions, potentially leading to price fluctuations in the affected stocks.
- Investor Focus: For those considering buying DAWN stock, analysts' opinions will serve as a crucial reference point, potentially impacting their investment strategies and market confidence.
- Source of Information: This rating change information is provided by Benzinga, highlighting the critical role analysts play in the market by helping investors gain a more comprehensive view of market conditions.
See More
Investor Rights Law Firm Investigates Transactions
- Potential Violation Investigation: Halper Sadeh LLC is investigating transactions involving Day One Biopharmaceuticals, Inc. selling to Servier for $21.50 per share and Talkspace, Inc. selling to Universal Health Services for $5.25 per share, which may involve breaches of fiduciary duties to shareholders.
- Shareholder Rights Protection: The law firm encourages shareholders to reach out to discuss their rights and options, promising legal consultations at no cost to ensure fair treatment in the transactions.
- Legal Fee Arrangement: Halper Sadeh LLC operates on a contingency fee basis, meaning shareholders will not have to pay upfront legal fees or expenses, thereby reducing their financial risk in pursuing claims.
- Global Investor Representation: The firm represents investors worldwide, focusing on combating securities fraud and corporate misconduct, and has successfully recovered millions for defrauded investors, showcasing its expertise in protecting investor rights.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Initiated: Halper Sadeh LLC is investigating Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) regarding its sale to Servier for $21.50 per share in cash, potentially infringing on shareholder rights, aiming to ensure fair treatment for investors.
- Shareholder Rights Protection: The firm is also scrutinizing Talkspace, Inc. (NASDAQ:TALK) in its sale to Universal Health Services, Inc. for $5.25 per share, urging shareholders to understand their rights and options to safeguard their interests.
- UniFirst Transaction Review: The sale of UniFirst Corporation (NYSE:UNF) to Cintas Corporation, offering $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, may prompt Halper Sadeh LLC to seek increased compensation and disclosures for shareholders to ensure transaction transparency.
- Global Investor Support: Halper Sadeh LLC represents investors worldwide, committed to combating securities fraud and corporate misconduct, having successfully recovered millions for victims in the past, highlighting its crucial role in protecting investor rights.
See More
Monteverde Law Firm Investigates Multiple Biopharma Companies
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the sale of Day One Biopharmaceuticals, with shareholders expected to receive $21.50 per share in cash, potentially providing significant financial returns and reflecting the company's market value in the biopharma sector.
- Medical Company Transaction: Shareholders of Select Medical Holdings are expected to receive $16.50 per share in cash, with the transaction led by Select Medical executives and directors, which may enhance the company's market position and boost shareholder confidence.
- FONAR Shareholder Returns: FONAR Corporation's Class B common stockholders will receive $19.00 per share, while Class C common stockholders will receive $6.34 per share, indicating a differentiated shareholder return strategy that could influence investor perceptions of the company's future.
- European Wax Center Acquisition: Shareholders of European Wax Center are expected to receive $5.80 per share in cash, with the transaction led by General Atlantic, which may provide new growth opportunities for the company while enhancing its competitiveness in the beauty industry.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Updates: The rating changes include upgrades, downgrades, and initiations, showcasing analysts' responsiveness to market dynamics, which may lead to short-term volatility in the affected stocks.
- Investor Focus: Investors considering buying VICI stock should pay attention to the latest analyst opinions, as these insights could provide crucial guidance for their investment decisions, particularly in the current market environment.
- Market Impact Analysis: Analyst rating changes typically have a direct impact on stock prices, prompting investors to closely monitor these shifts to adjust their investment strategies accordingly.
See More
Monteverde Law Firm Investigates Multiple Biopharmaceutical Companies
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the sale of Day One Biopharmaceuticals, Inc., where shareholders are expected to receive $21.50 per share in cash, providing substantial returns and enhancing market confidence in the biopharmaceutical sector.
- Merger Transaction Analysis: The merger between CECO Environmental Corp. and Thermon Group Holdings, Inc. is expected to grant CECO shareholders approximately 62.5% ownership in the combined company, significantly boosting CECO's market position in the environmental sector.
- Cash Acquisition Opportunity: Enhabit Inc.'s sale to Kinderhook Industries, LLC is projected to yield $13.80 per share for shareholders, reflecting a direct cash return that indicates market confidence in Enhabit's future growth prospects.
- Capital Investment Outlook: The transaction involving KORE Group Holdings, Inc. with Searchlight Capital Partners, L.P. and Abry Partners is expected to provide shareholders with $9.25 per share, offering stable cash flow and enhancing KORE's attractiveness in the capital markets.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these stocks.
- Market Dynamics Overview: While specific stock names are not mentioned, changes in analyst ratings typically influence investor decisions, potentially leading to price fluctuations in the affected stocks.
- Investor Focus: For those considering buying DAWN stock, analysts' opinions will serve as a crucial reference point, potentially impacting their investment strategies and market confidence.
- Source of Information: This rating change information is provided by Benzinga, highlighting the critical role analysts play in the market by helping investors gain a more comprehensive view of market conditions.
See More
Investor Rights Law Firm Investigates Transactions
- Potential Violation Investigation: Halper Sadeh LLC is investigating transactions involving Day One Biopharmaceuticals, Inc. selling to Servier for $21.50 per share and Talkspace, Inc. selling to Universal Health Services for $5.25 per share, which may involve breaches of fiduciary duties to shareholders.
- Shareholder Rights Protection: The law firm encourages shareholders to reach out to discuss their rights and options, promising legal consultations at no cost to ensure fair treatment in the transactions.
- Legal Fee Arrangement: Halper Sadeh LLC operates on a contingency fee basis, meaning shareholders will not have to pay upfront legal fees or expenses, thereby reducing their financial risk in pursuing claims.
- Global Investor Representation: The firm represents investors worldwide, focusing on combating securities fraud and corporate misconduct, and has successfully recovered millions for defrauded investors, showcasing its expertise in protecting investor rights.
See More
